会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
    • 细胞抗原和靶信号转导蛋白的复合谱,用于分析和临床管理血液癌
    • US20070105165A1
    • 2007-05-10
    • US11267948
    • 2005-11-04
    • Charles GoolsbyT. ShankeyDavid HedleyJames JacobbergerStanley Shackney
    • Charles GoolsbyT. ShankeyDavid HedleyJames JacobbergerStanley Shackney
    • G01N33/574
    • G01N33/57426G01N33/5052G01N2800/52
    • The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).
    • 本发明涉及用于建立来自疑似具有肿瘤状况的个体的样品的复合标记物谱的方法。 本发明的复合标记物分布允许鉴定预后和治疗相关的肿瘤病症亚组和个体临床病程的预测。 本发明的方法提供了用于选择患有肿瘤病症的个体的治疗的工具,包括分配风险组的方法,预测复发风险增加的方法,预测发生继发性并发症的风险增加的方法,方法 选择个体治疗的方法,确定个体治疗功效的方法以及确定个体预后的方法。 特别地,本发明的方法公开了一种建立复合标记物谱的方法,该方法可用作预后指标以预测个体肿瘤状况的进程是否是侵略性或惰性的,由此帮助临床医师管理 患者和评估使用的治疗方式。 在本文公开的特定实施方案中,本发明的方法涉及建立选自慢性淋巴细胞性白血病(CLL),急性骨髓性白血病(AML),慢性骨髓性白血病(CML)和 急性淋巴细胞性白血病(ALL)。
    • 2. 发明申请
    • Composite Profiles of Cell Antigens and Target Signal Transduction Proteins for Analysis and Clinical Management of Hematologic Cancers
    • 复合型细胞抗原和目标信号转导蛋白用于分析和临床管理的血液癌
    • US20100261204A1
    • 2010-10-14
    • US12696702
    • 2010-01-29
    • Charles GOOLSBYT. Vincent ShankeyDavid HedleyJames JacobbergerStanley Shackney
    • Charles GOOLSBYT. Vincent ShankeyDavid HedleyJames JacobbergerStanley Shackney
    • G01N33/574
    • G01N33/57426G01N33/5052G01N2800/52
    • The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).
    • 本发明涉及用于建立来自疑似具有肿瘤状况的个体的样品的复合标记物谱的方法。 本发明的复合标记物分布允许鉴定预后和治疗相关的肿瘤病症亚组和个体临床病程的预测。 本发明的方法提供了用于选择患有肿瘤病症的个体的治疗的工具,包括分配风险组的方法,预测复发风险增加的方法,预测发生继发性并发症的风险增加的方法,方法 选择个体治疗的方法,确定个体治疗功效的方法以及确定个体预后的方法。 特别地,本发明的方法公开了一种建立复合标记物谱的方法,该方法可用作预后指标以预测个体肿瘤状况的进程是否是侵略性或惰性的,由此帮助临床医师管理 患者和评估使用的治疗方式。 在本文公开的特定实施方案中,本发明的方法涉及建立选自慢性淋巴细胞性白血病(CLL),急性骨髓性白血病(AML),慢性骨髓性白血病(CML)和 急性淋巴细胞性白血病(ALL)。